Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company's pipeline includes potential best-in-class small molecules and antibody-drug conjugates (ADCs). Avenzo's small molecule inhibitors, AVZO-021 and AVZO-023, are novel, highly potent and selective inhibitors of CDK2 and CDK4, respectively, which are key enzymes involved in cell cycle regulation.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/22/25 | $60,000,000 | Series B |
Deep Track Capital Delos Capital Foresite Capital INCE Capital Lilly Asia Ventures Longwood Fund New Enterprise Associates OrbiMed Advisors  Quan Capital Sands Capital SR One Surveyor Capital TF Capital | undisclosed |
